A Phase II Study of Bevacizumab (rhuMab VEGF, NSC 704865), Idarubicin and Cytarabine in Patients With Chronic Myeloid Leukemia in Blast Phase
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Bevacizumab (Primary) ; Cytarabine; Idarubicin
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 30 Jan 2013 New trial record